Ben Kong: Our ovarian clear cell carcinoma (OCCC) cohort revealed elevated HER2 expression with or without genomic amplification in 4/5 cases
Ben Kong, Clinical Pharmacy Specialist at
“We are excited to share and invite you to review our ASCO24 abstract titled, ‘Multiomic analysis in ovarian clear cell carcinoma to gain insight into biology and therapeutic opportunities.’
Conclusion – ‘Our ovarian clear cell carcinoma (OCCC) cohort revealed elevated HER2 expression with or without genomic amplification in 4/5 cases. Two participants experienced clinical benefit when treated with trastuzumab deruxtecan, supporting further exploration of HER2 antibody drug conjugates in this aggressive disease. More study is needed to determine the frequency of HER2 overexpression and amplification in OCCC, the importance of HER2 on OCCC pathophysiology, and the therapeutic benefit of targeting HER2 in this population.'”
Read further.
Source: Ben Kong/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023